Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan-minocycline Dual Therapy vs Bismuth-based Quadruple Therapy for H. Pylori Eradication
NCT07904429Phase 3Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of keverprazan and minocycline in Helicobacter pylori infection (3 arms), sponsored by Nanjing First Hospital. Primary endpoints: Helicobacter pylori eradication rate, Patient adherence at day 14 and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
keverprazanminocycline
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07904429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904429.